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Abstract: Glomerulonephritis is a common cause of chronic kidney disease and end stage renal 
failure. Current therapy relies on variably effective, nonspeciﬁ  c and toxic immunosuppression. 
Recent insights into underlying biology and disease pathogenesis in human glomerulonephritis 
combined with advances in the ﬁ  elds of inﬂ  ammation and autoimmunity promise a cadre of 
novel targeted interventions. This review highlights the therapeutic potential of two antigens, 
alpha3 (IV)NC1 collagen and podocyte neutral endopeptidase, and two cell signaling and 
effector molecules, IgG Fc receptors and complement, judged to be particularly amenable to 
therapeutic manipulation in man. It is anticipated that continued dissection of pathogenesis in 
the diverse disorders that comprise the glomerulonephritides will provide the basis for indi-
vidualized disease-speciﬁ  c therapy.
Keywords: glomerulonephritis, immunotherapy, Goodpasture syndrome, membranous 
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Introduction
Glomerulonephritis encompasses a cluster of diseases that have been described as the 
most common single cause of end stage renal disease (ESRD) in the world (Timoshanko 
and Tipping, 2005). GN was listed as the cause of ESRD in over 70,000 US patients 
in 2004 (US Renal Data System 2007). Glomerulonephritis and hypertension together 
are also the most common causes of chronic kidney diseases (CKD) in developing 
countries, and GN trails only hypertension and diabetes as a leading cause of CKD 
in the US, Europe, and Japan. Notably, for every patient with clinical GN, an esti-
mated 5–10 patients have undiagnosed subclinical disease (Couser 1999). It is thus 
striking that an estimated 26 million Americans, or 13% of the US adult population, 
and over 50 million individuals worldwide have CKD (Dirks et al 2005; Coresh et al 
2007). Chronic GN may underlie pathogenesis of CKD in a signiﬁ  cant proportion of 
this population. CKD not only places patients at risk for the various complications 
of renal damage, including increased cardiovascular disease and mortality, but it is 
estimated that each year more than one million CKD patients develop ESRD. Survival 
with ESRD requires renal replacement therapy with dialysis or transplantation, costly 
medical interventions not available in many developing countries. Clearly, effective 
therapy for GN would have signiﬁ  cant impact globally on human health and health 
care ﬁ  nancing.
GN is particularly prevalent among renal allograft recipients (Briganti et al 2002; 
Couser 2005). Glomerular diseases, including diabetes and glomerulonephritis, account 
for over 70% of patients receiving renal allografts, and in some countries GN alone 
accounts for up to 50% of patients (Briganti et al 2002). In a recent review of the 
Australian registry, among 1505 pts with biopsy-proven GN receiving a primary renal 
transplant between 1988 and 1997, recurrent or de novo GN occurred in 6%–20% of 
patients. Recurrence was the third most frequent cause of allograft loss at 10 years, after Biologics: Targets & Therapy 2008:2(3) 532
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chronic rejection and death with a functioning transplant. 
Among patients transplanted due to GN, 8.4% lost their 
allograft to recurrent GN by 10 years (Briganti et al 2002). 
These patients may particularly beneﬁ  t from novel targeted 
therapies, since disease onset can be readily identiﬁ  ed and 
intervention initiated promptly, if not pre-emptively.
Deﬁ  nition of glomerulonephritis
The glomerulonephritides comprise a group of immunologic 
diseases that damage the renal glomerulus, the ﬁ  ltering unit 
of the kidney. This network of capillaries, fed and drained 
by the afferent and efferent arterioles, respectively, ﬁ  lters 
plasma across the fenestrated endothelium, glomerular 
basement membrane (GBM) and podocyte slit diaphragms 
to collect in Bowman’s space. Filtrate is dramatically modi-
ﬁ  ed as it passes through a series of tubules before delivery 
to the renal pelvis for excretion. The approximately 2 
million glomeruli in normal adult kidneys ﬁ  lter over 150 
liters of plasma per day. With this constant exposure and 
high ﬁ  ltering capacity, it is perhaps not surprising that the 
glomerulus is susceptible to injury from immune cells and 
their soluble products.
GN is deﬁ  ned as inﬂ  ammation and cell proliferation 
in the glomerulus, although injury typically extends to 
the renal tubules, interstitium and vasculature. Common 
clinical findings include hematuria, proteinuria, and/or 
decreased glomerular ﬁ  ltration rate, detected as elevation in 
creatinine, often accompanied by hypertension, edema, and 
disease-speciﬁ  c ﬁ  ndings. Immunopathogenesis is generally 
attributed to autoimmunity (see below), exacerbated by a 
local renal immune and inﬂ  ammatory response. Common 
entities categorized as GN are indicated in Table 1. These 
include both renal-limited diseases and nephritides that 
develop as part of a systemic disorder, as well as those that 
have both renal-limited and systemic forms, such as anti-
GBM nephritis and its systemic counterpart, Goodpasture 
syndrome. Table 1 also includes several additional glomeru-
lopathies with presumed immunologic origins but that are 
considered noninﬂ  ammatory because they lack prominent 
cellular proliferation and inﬁ  ltrates on renal histopathologic 
examination. These entities are often treated with immuno-
suppression regimens similar to those used to treat GN and 
thus are included in this review.
Current therapies for GN comprise a modest list of 
broadly immunosuppressive agents (Table 2). Efﬁ  cacy can 
be striking, as observed with the combination of steroids 
and cyclophosphamide, and more recently mycophenolate 
mofetil, for induction and maintenance therapy in lupus 
nephritis and the ANCA vasculitides. Newer drugs devel-
oped initially to abrogate alloimmunity in transplantation 
have also proven effective in subsets of GN patients refrac-
tory to or intolerant of older established drugs. Nonetheless, 
these interventions support broad, non-speciﬁ  c blockade of 
the immune and inﬂ  ammatory networks, demonstrate vari-
able and often unpredictable efﬁ  cacy, and carry signiﬁ  cant 
toxicities, including infection, cancer, osteoporosis, avas-
cular necrosis, amenorrhea, sterility, and alopecia. Clearly, 
more speciﬁ  c safer interventions are urgently needed for 
this diverse group of diseases. It is therefore notable that 
a variety of promising new approaches to restore speciﬁ  c 
immune tolerance to autoantigens, using protein-, cellular-, 
or gene-based therapies, have entered the clinical arena for 
multiple autoimmune diseases (Wolfraim 2006). Therapy for 
GN has lagged in this area, in part because the target antigens 
in most human immune nephritides remain elusive, unlike 
their experimental counterparts, and in part because little is 
Table 2 Current common nonspeciﬁ  c therapies for glomerulo-
nephritis
Glucocorticoids
Cyclophosphamide
Azathioprine
Chlorambucil
Intravenous immunoglobulin (IVIG)
Plasma exchange
Protein A immunoadsorption
Mycophenolate mofetil
Cyclosporine
Tacrolimus
Rapamycin
Table 1 Common glomerulonephritides and glomerulopathies 
with immune origins
Renal-limited disease
 IgA  nephropathy
  Membranoproliferative glomerulonephritis (MPGN)
  Anti-glomerular basement membrane disease
 Pauci-immune  glomerulonephritis
Systemic disease
 Postinfectious  glomerulonephritis
 Lupus  nephritis
  Henoch-Schonlein purpura (HSP)
 Goodpasture  syndrome
 Wegener’s  granulomatosis
 Microscopic  polyangiitis
 Cryoglobulinemia
Additional glomerulopathies with immune origins
 Membranous  Nephropathy
  Subset of focal sclerosing glomerulosclerosis (FSGS)
  Subset of minimal change disease
  Light chain deposition diseaseBiologics: Targets & Therapy 2008:2(3) 533
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known about immune regulatory mechanisms controlling 
nephritogenic lymphocytes. Our goal in this review is to 
examine in detail two antigens, alpha3 (IV)NC1 collagen 
and neutral endopeptidase, and two signaling and effector 
molecules, FcγR and complement, that are judged to be 
particularly amenable for novel therapeutic intervention in 
GN in man. The reader is referred to other recent reviews 
(Javaid and Quigg 2005; Foster 2007) and Table 3 for a 
more comprehensive cataloguing of potential biologic 
interventions in GN.
Glomerulonephritis: pathogenesis 
and potential therapeutic targets
Considerable research in this ﬁ  eld is focused on understanding 
the basic biology and pathogenesis of GN. Animal models 
have been particularly informative, both in highlighting the 
role of autoimmunity in the development of most GN and in 
providing in vivo tools with which to dissect the complex 
cell interactions that perpetuate disease and speciﬁ  c effector 
mechanisms that mediate tissue injury and inﬂ  ammation. 
These models have revealed multiple targets for interven-
tion, with disease speciﬁ  city determined by the initiating 
antigen, the specific receptors on responding B and T 
lymphocytes, the glomerular antigen targeted locally, and 
the subset of downstream effectors recruited in a particular 
disease or individual (Figure 1).
Three of the most extensively studied animal models 
of nephritis involve antibody interactions with intrinsic 
glomerular protein. Autoimmune responses to glomerular 
basement membrane (GBM) alpha3 (IV) collagen and to 
glomerular epithelial cell (podocyte) membrane antigens 
can be induced by active immunization of animals with 
heterologous or autologous kidney extract. Resulting autoan-
tibodies lead to nephritis marked by linear GBM Ig deposits 
(eg, autoimmune anti-GBM Ig-mediated disease) or disease 
dominated by granular subepithelial deposits (eg, active 
Heymann nephritis), respectively. Nonautoimmune nephritis 
with similar histopathologic characteristics can be induced 
by passive administration of preformed antigen-reactive 
antibodies. A third model, mesangioproliferative nephritis, 
is induced in rats by passive administration of antibodies that 
recognize a rat mesangial cell phosphatidylinositol-anchored 
glycoprotein, termed Thy-1 antigen.
These models, as well as the spontaneous murine lupus 
models, provide considerable insight and are excellent tools 
with which to study downstream effector pathways. The spe-
ciﬁ  c mediators engaged vary by species, strain, and antigen 
preparation, and collectively effectively model the hetero-
geneous nephritis phenotypes observed in man (Table 1). 
Conversely, the models that depend on passive transfer of 
differentiated effectors or Ig provide minimal insight into 
the events that initiate and regulate renal-restricted autoim-
munity. Also of unclear relevance to spontaneous human 
disease is the use of potent adjuvant in active immunization 
models. Elucidation of tolerance mechanisms that regulate 
nephritogenic autoreactivity will require novel autoreactive 
Table 3 Potential immunotherapy in autoimmunity and glomeru-
lonephritis (after Foster 2007)
1. B and T cell signaling and activation thresholds
  Upregulation or stimulation of B cell inhibitory Fc gamma RIIB
B cell tolerance induction [oral alpha3 (IV)NC1 collagen, dsDNA 
tetramers]a
  Inhibition of DNA methylation or histone deacetylationb
2. B and T cell survival, proliferation and differentiation
  Anti-B cell therapy (anti-CD20 and anti-CD19 mAb)
Blockade of BAFF/BAFF receptor pathway (anti-BAFF mAb; TACI-Ig 
fusion protein)
   Modulate activating or inhibitory surface receptors (anti-CD22 mAb)
  Anti-T cell subset therapy
Blockade of costimulator pathways (CTLA4-Ig, anti-CD40L or 
anti-ICOSL mAb)
  Stimulation of T cell inhibitory pathways PD-1/PD1-L, CTLA4, BTLA
  Modulation of TLR signaling (inhibitory GpG oligodeoxynucleotides)
 Modiﬁ  ed antigen presenting cells (dendritic cell therapy)
  Cytokine or anti-cytokine therapy
3. Regulatory cell function
  In vivo or ex vivo induction of regulatory T or B cells
Administration of tolerizing self-antigen-expressing dendritic or stem 
cells or B lymphocytes
4. Effector cell function and inﬂ  ammation
  Blockade of Ig production
  Inhibition of memory or plasma cell differentiation
  Blockade or adsorption of autoantibody reactivity
Complement inhibition (anti-C5 mAb, soluble inhibitors, C5aR 
antagonist)
  Blockade of activating FcgRI, FcgRIII or (mouse) FcgRIV
  Stimulation or upregulation of inhibitory FcgRIIB
Cryo-engineered, IgG isotype-restricted, or synthetic (pooled designer 
mAb) IVIG
Inhibition of secondary mediators (cytokines, chemokines, NO, ROS, 
lipid mediators, etc)
  Anti-macrophage or neutrophil therapy
  Adhesion molecule blockade (anti-CD11a, anti-ICAM-1)
  T helper subset skewing (rIL-10)
  Cytokine blockade (anti-TNFalpha, TNFR2-Ig, IL-1ra)
5. Intrinsic renal cell activation and proliferation
  Blockade of growth factors (PDGF), chemokines, cell cycle proteins
Upregulation or targeted localization of complement regulatory 
proteins
  Downregulation or blockade of activating FcgR
aSelected examples of interventions currently in preclinical or clinical trials are in 
parentheses.
bSome interventions modulate multiple checkpoints; for simplicity, only one category 
is shown.
Abbreviations: TLR, toll-like receptor; PD-1, programmed death-1; CTLA-4 
(cytotoxic T lymphocyte antigen-4); BTLA, B and T lymphocyte attenuator.Biologics: Targets & Therapy 2008:2(3) 534
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lymphocyte receptor transgenic models that target the 
relevant kidney antigens (Rudolph et al 2002; Zhang et al 
2006).
Antigen-based approaches
Kidney antigen is an obvious target for achieving speciﬁ  city 
in treating GN. Animal models engage a variety of cell-bound 
or soluble antigens either native to the glomerulus or that 
deposit on glomerular structures (Table 4). It is likely that 
similar antigens are involved in human GN, although to date 
only two classes of antigens have been conﬁ  rmed in human 
disease: the noncollagenous (NC1) domains of the alpha 
3 and 5 chains of type IV collagen in anti-GBM nephritis, 
and neutral endopeptidase in the rare but highly informative 
antenatal membranous nephropathy. These antigens will be 
considered in turn below, with regard to their therapeutic 
exploitation.
Anti-GBM GN and Goodpasture 
syndrome
The best characterized and until recently only conﬁ  rmed 
kidney target in human GN is alpha3 (IV)NC1 collagen. 
A pathologic autoimmune response to this antigen leads to 
focal segmental proliferative and necrotizing GN, frequently 
with crescent formation. This is associated with linear IgG 
deposition along the GBM, a pathologic hallmark of the 
disease. Co-involvement of the alveolar basement membrane 
with resultant pulmonary hemorrhage is termed Goodpas-
ture syndrome (GPS). This restricted organ involvement 
is directly related to the restricted tissue expression of the 
target antigen.
Over the past two decades the molecular nature of the 
speciﬁ  c epitopes targeted by patient autoantibodies has been 
carefully dissected. The GBM collagen network is composed 
of heterotrimers of alpha3, alpha4 and alpha5 chains of type 
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Figure 1 Pathogenesis of glomerulonephritis.   Animal models suggest that autoimmunity underlies pathogenesis of most GN. Disease initiation requires loss of tolerance and 
activation of self-reactive lymphocytes. Activated B and T cells interact to promote autoantibody and cytokine production, immune complex formation, antibody deposition, 
macrophage and neutrophil recruitment, renal inﬂ  ammation, and activation of renal endothelial, mesangial, epithelial and tubular cells. Glomerular and tubulointerstitial antigens 
may be speciﬁ  cally targeted by autoantibodies and self-reactive CD4 and CD8 TCR alpha/beta effector T cells, gamma/delta T cells and NKT cells. Numerous soluble and 
cellular mediators participate in subsequent tissue inﬂ  ammation, injury and repair, and modulate local renal immune responses. The predominant cells and molecules engaged 
vary depending on the etiology and site of glomerular injury.Biologics: Targets & Therapy 2008:2(3) 535
Therapy for glomerulonephritis
IV collagen. Trimers self associate at their NC1 carboxyl 
termini, forming NC1 hexamers, and at their amino termini, 
forming a collagen IV network. The epitopes recognized by 
the high afﬁ  nity IgG autoantibodies isolated from serum 
and kidney eluates of GPS patients have been localized to 
the NC1 domain of the alpha3 (IV) chain (Wieslander et al 
1984; Saus et al 1988). These pathogenic epitopes are confor-
mational and partially sequestered within the NC1 hexamer, 
minimally accessible for autoantibody binding unless hex-
amer dissociation into dimers or monomers exposes critical 
hydrophobic residues (David et al 2001; Borza et al 2002; 
Borza and Hudson 2003; Borza et al 2005). Environmental 
or genetic inﬂ  uences that facilitate hexamer dissociation may 
underlie disease susceptibility (Wilson 1997; Borza et al 
2005; Kalluri et al 2000a). Binding to accessible hydrophilic 
residues by low afﬁ  nity autoantibodies may also promote 
pathogenic epitope exposure by inducing conformational 
changes and stabilizing monomers (Borza et al 2000). Two 
immunodominant antibody epitopes recognized by the major-
ity of GPS patient sera have been mapped using chimeric 
proteins bearing segments of the alpha3 (IV) chain super-
imposed on a nonimmunoreactive alpha1(IV)NC1 collagen 
framework (Hellmark et al 1999; Netzer et al 1999; Borza 
et al 2000). A restricted number of target epitopes is sup-
ported by demonstration of a shared idiotype, and thus shared 
structural determinant, among GPS serum autoantibodies 
(Meyers et al 1998).
Epitope and antibody characteristics suggest several 
targets for speciﬁ  c therapy in anti-GBM nephritis. Selec-
tive immunoadsorption using afﬁ  nity columns coated with 
antigen can rapidly reduce circulating autoantibody titers in 
active disease. As proof of concept, afﬁ  nity chromatography 
using either puriﬁ  ed bovine or recombinant human alpha3 
(IV)NC1 collagen completely and selectively depletes 
pathogenic autoantibodies from patient plasma (Boutaud 
et al 1996). Feasibility of this approach in the clinic is further 
suggested by the success of repetitive immunoadsorption in 
removing plasma anti-A or anti-B isotype agglutinins in man; 
when combined with standard anti-rejection immunosup-
pression, immunoadsorption permits long-term survival of 
ABO-incompatible kidney allografts (Donauer et al 2006). 
This approach has an advantage over the current practice of 
initiating plasmapheresis in acute GPS, in that it does not 
deplete protective anti-microbial IgG, a major concern in a 
patient receiving concurrent cyclophosphamide.
Administration of oral or nasal GBM, bovine alpha3
(IV)NC1 dimers or recombinant rat alpha3 (IV)NC1 collagen 
can prevent induction of anti-GBM nephritis in antigen-
immunized rodents (Kalluri et al 1997; Reynolds and Pusey 
2001; Reynolds et al 2005). The tolerance mechanisms 
remain unclear, although downregulation of Th1 T cell 
responses is implicated. This approach may have particu-
lar utility as pre-emptive therapy in a subset of patients in 
whom onset of antibody production can be anticipated, 
such as Alport patients undergoing renal transplantation 
(see below). The consequences of antigen administration 
in active disease are less clear and require further study to 
understand the potential for triggering allergic or pathogenic 
stimulatory signals.
Antigen-based interventions in lupus nephritis, which 
has been most extensively studied, are instructive. Proposed 
approaches include neutralization or depletion of antigen-
reactive autoantibodies, B cells, or T cells, using infusion 
of soluble antigen, peptide epitopes, antigen multimers or 
anti-idiotypic antibodies, either alone or linked to cytotox-
ins. It is reasoned that autoantigen epitopes recognized by 
pathogenic B and T cells can delay or reverse disease if 
administered in a dose and form that can anergize or delete 
pathogenic cells or induce inhibitory regulatory cells. In 
this regard, in lupus mice onset of nephritis can be delayed 
by biweekly subcutaneous administration of sub-nanomolar 
quantities of nucleosomal histone peptide (Kang et al 2005) 
or by intravenous injection of high doses of a synthetic 
consensus peptide based on unique T-cell stimulatory 
epitopes expressed within anti-DNA IgG variable regions 
(Hahn et al 2001). Immunization with peptide epitopes from 
anti-nucleosomal IgG variable regions has a similar effect 
(Stoll et al 2007). Tolerance depends in part on induction 
of antigen-speciﬁ  c regulatory CD4+CD25+ T cells and 
CD8+ inhibitory T cells that secrete TGF-beta (La Cava 
et al 2004, 2005; Hahn et al 2005; Kang et al 2005). IL-10+ 
Table 4 Antigen targets in immune-mediated glomerular injury
Experimental models Human
Basement membrane antigens
 Collagen,  laminin
 Heparan  sulfate
 Proteoglycan,  chondroitin  A
Basement membrane antigens
Alpha3 (IV)NC1
(GPS,   ARAS allograft)
   Alpha5(IV)NC1 (XLAS allograft)
Intrinsic renal cell antigens
 Endothelial  cell
 Mesangial  cell
  Podocyte (proteins, glycolipids)
Intrinsic renal cell antigens
Neutral endopeptidase
(antenatal MN)
Soluble nuclear antigens
  DNA, histone, nucleosome
Soluble immune elements
  Autologous Ig, C1q
Abbreviations: GPS, Goodpasture syndrome; ARAS, Autosomal recessive Alport 
syndrome; XLAS, X-linked Alport syndrome; MN, membranous nephropathy.Biologics: Targets & Therapy 2008:2(3) 536
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regulatory T cells induced by nasal histone peptide (Wu et al 
2002) or high dose intravenous ribonucleoprotein peptide 
(Riemekasten et al 2004) are reported to provide protec-
tion in the (SWRxNZB)F1 and (NZBxNZW)F1 models of 
lupus nephritis, respectively. Murine lupus nephritis is also 
delayed by injection of a 21-mer laminin peptide recognized 
by a subset of pathogenic murine lupus autoantibodies 
(Amital et al 2005). The antigen peptide is located within 
the laminin alpha1 chain expressed in normal adult kidney 
mesangium and diseased GBM (Abrahamson et al 2003). 
In lupus patients, levels of anti-laminin autoantibodies cor-
relate with disease activity and can be effectively removed 
by peptide-speciﬁ  c immunoadsorption (Amital et al 2007). 
In early human trials, lupus nephritic ﬂ  ares were prevented 
by administration of double stranded DNA tetramers that 
putatively adsorb and remove anti-DNA IgG and anti-DNA 
B cells (Alarcon-Segovia et al 2003); phase III clinical trials 
testing this reagent are ongoing (Furie 2006).
Alport syndrome, alloantibodies
and post-transplant anti-GBM GN
Collagen epitopes also may be targeted therapeutically in 
patients with Alport syndrome who develop ESRD and 
undergo kidney transplantation. Alport patients develop a 
hereditary nephritis due to mutations in one of the genes 
encoding the alpha chains (alpha3, alpha4, or alpha5) of type 
IV collagen of the GBM (Hudson et al 2003). Ultrastructur-
ally this is manifest as splitting, thickening and thinning of 
the involved basement membranes. Clinical consequences 
are related to the tissue distribution of these alpha(IV) chains 
and include progressive renal failure, sensorineural deaf-
ness and/or ocular abnormalities. Because Alport patients 
lack the corresponding collagen proteins and thus lack the 
Goodpasture epitopes in their native basement membranes 
(Olson et al 1980; McCoy et al 1982), those who undergo 
renal transplantation typically develop alloantibodies that 
bind GBM in the allograft but not the native kidneys. Of 
these, 3%–5% of patients will also develop anti-GBM GN, 
despite concurrent post-transplant immunosuppression. 
Although not all alloantibody target epitopes are known, 
alloantibody reactivity to NC1 domains of all three alpha 
chains (alpha3, alpha4, or alpha5) is reported (Kalluri et al 
2000b). Anti-alpha3 (IV)NC1 alloantibodies eluted from the 
failed renal allograft of one patient with autosomal recessive 
Alport syndrome and post-transplant anti-GBM GN recog-
nized alloepitopes distinct from Goodpasture autoepitopes 
(Wang et al 2005). Thus, Alport patients in particular may 
beneﬁ  t from targeted therapies, since disease onset can be 
readily identiﬁ  ed and intervention initiated promptly, if not 
pre-emptively.
Membranous nephropathy
Membranous nephropathy (MN) is a common cause of 
CKD and accounts for approximately 20% of nephrotic syn-
drome in adult Caucasians (Ponticelli, 2007). By 10 years, 
20%–40% of patients progress to ESRD. Given this con-
siderable disease burden, novel effective disease-speciﬁ  c 
therapies are urgently needed. Important insight into disease 
pathogenesis was gleaned from study of the rat Heymann 
nephritis models (Couser and Nangaku 2006). Active HN 
is induced experimentally by immunization with kidney 
antigen preparations. Immunized rats develop marked pro-
teinuria and glomerular pathology almost indistinguishable 
from human MN: thickened glomerular capillary basement 
membranes due to immune deposition exclusively in the 
subepithelial space. While it was initially believed that the 
granular deposits resulted from passive deposition of circu-
lating immune complexes, key experiments subsequently 
revealed that antibody perfusion of isolated rat kidney led to 
immediate in situ formation of glomerular deposits (Couser 
et al 1978; Van Damme et al 1978). The target antigens 
were subsequently identiﬁ  ed as megalin, a large membrane 
glycoprotein, multiligand endocytic receptor and member of 
the LDL-receptor-superfamily, and the receptor-associated 
protein, RAP, constitutively expressed on the rat glomerular 
podocyte foot processes (Kerjaschki and Farquhar 1982; 
Saito et al 1994; Farquhar et al 1995). Circulating pathogenic 
antibodies traverse the GBM, bind the megalin-RAP protein 
complex within the podocyte clathrin-coated pits, and shed 
as immune complexes that attach to the GBM. Additional 
autoantibodies in serum of rats with Heymann nephritis con-
tribute to disease by binding distinct epitopes in the podocyte 
membrane including glycolipid and integrins to activate 
complement and induce proteinuria (Susani et al 1994).
Elucidation of pathogenesis in Heymann nephritis spurred 
a search for podocyte targets in human idiopathic MN. Mega-
lin is not a candidate; although it is found in human renal 
proximal tubules, it has not been detected in human glomeruli 
or in immune deposits in patients with MN (Kerjaschki et al 
1987). Alternative candidates include dipeptidyl-peptidase 
IV and neutral endopeptidase (NEP), both of which are 
expressed on human podocytes and implicated in glomeru-
lar immune deposition in experimental models (Ronco et al 
1989; Ronco et al 1994), as well as unknown podocyte tar-
gets. NEP, an approximately 90 Kd membrane-bound ectoen-
zyme, was recently identiﬁ  ed as target antigen in a rare form Biologics: Targets & Therapy 2008:2(3) 537
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of antenatal membranous nephropathy (Debiec et al 2002). 
Affected infants have subepithelial immune deposits and pro-
teinuria at birth. Their mothers are phenotypically normal but 
genetically deﬁ  cient in NEP due to truncating mutations in 
the Membrane MetalloEndopeptidase (MME) gene (Debiec 
et al 2004). During pregnancy, the fetus expresses normal 
NEP protein, the gene for which is inherited from the father. 
NEP-deﬁ  cient mothers become alloimmunized to NEP in 
the placental syncytiotrophoblast and fetal tissues. Maternal 
anti-NEP IgG are transported across the placenta to the fetal 
circulation during the third trimester, cross the fetal GBM 
to bind NEP-expressing podocytes in developing glomeruli, 
and form immune complexes similar to those observed in 
experimental HN.
Therapeutic and diagnostic implications 
of NEP-induced MN
Two immunodominant linear peptide NEP epitopes recog-
nized by serum of alloimmunized mothers have been identi-
ﬁ  ed to date (Debiec and Ronco 2007). These epitopes may 
provide a basis for antigen-based therapies to prevent kidney 
injury in fetuses at risk. It is proposed that mothers of affected 
infants be monitored for circulating anti-NEP antibodies 
during subsequent pregnancies (Ronco and Debiec 2007). 
Rising titers can be managed either nonspeciﬁ  cally by plasma 
exchange, or in an antigen-speciﬁ  c manner using repetitive 
antigen adsorption. It is further proposed that undetected 
NEP-deﬁ  ciency in transplant recipients with subsequent NEP 
alloimmunization may account for some cases of de novo MN 
in kidney allografts. Alloimmunization may similarly play a 
role in MN that develops after bone marrow or hematopoietic 
stem cell transplantation (Ronco and Debiec 2007). The 
degree to which maternal NEP-deﬁ  ciency contributes to CKD 
in the general population is unknown, but likely to be low. 
However, observations from antenatal MN have rekindled 
hopes that nephritogenic podocyte antigens responsible for 
adult-onset MN will be identiﬁ  ed, and ultimately provide 
novel targets for antigen–speciﬁ  c therapy.
IgG Fc gamma receptors (FcγR)
and complement as therapeutic 
targets in GN
A large number of cellular and soluble mediators and modu-
lators of immunity and inﬂ  ammation and cell activation are 
implicated in immune activation, tissue destruction, remod-
eling and repair in GN (Fig. 1). Each of these is a potential 
target for therapeutic intervention (Table 3). The discussion 
below focuses on two modulators, IgG Fc gamma receptors 
(FcγR) and complement, that are particularly amenable to 
therapeutic manipulation and for which a variety of thera-
peutic modulators are already in preclinical or early clinical 
trials.
Notably, whereas the discussion below focuses primarily 
on the role of FcγR and complement as effectors of renal 
inﬂ  ammation, both molecules also modulate activation of 
B cells and follicular dendritic cells and thus have potent 
effects on humoral autoimmunity. Both cell types express 
inhibitory FcγRIIB that engages IgG as well as complement 
receptors type 1 (CR1, or CD35) and type 2 (CR2, CD21) 
that recognize activated products of C3 and C4 (reviewed 
in Nimmerjahn and Ravetch 2006, Roozendaal and Carroll, 
2007). Thus, manipulation of these receptor-ligand interac-
tions can alter initial lymphocyte tolerance and activation as 
well as modulate local renal effector mechanisms.
FcγR
IgG receptors link IgG or IgG immune complexes to 
effector cells by binding the CH2 domain of the Ig heavy 
chain constant, or Fc, region (Ravetch and Bolland 2001). 
FcγR are constitutively expressed on several cell types that 
contribute to pathogenesis in nephritis, including macro-
phages, dendritic cells, neutrophils, mast cells, endothelial 
cells and B cells, but not T lymphocytes (Nimmerjahn and 
Ravetch 2007). There is also evidence that FcγR may be 
cytokine-inducible on parenchymal cells, including human 
mesangial cells (Radeke et al 1994). Many FcγR-bearing 
cells co-express two functional classes of FcγR: activating 
and inhibitory. Most activating receptors, FcγRI, FcγRIII, 
FcγRIIA and mouse FcγRIV, transmit signals via an adaptor 
protein, typically the common gamma chain coreceptor, that 
contains an ITAM (Immunoreceptor Tyrosine-based Activat-
ing Motif). FcγRIIIB is unique in being glycosylphosphatidyl 
inositol-anchored with selective expression on neutrophils 
and eosinophils. The one inhibitory receptor, FcγRIIB, is 
a single chain receptor that transmits signals through an 
ITIM, or inhibitory motif. The balance of signaling from the 
two types of receptors sets the threshold for cell activation 
after stimulation by IgG or IgG-immune complexes. B cells 
express only inhibitory FcγRIIB, which negatively regulates 
activating signals from the B cell receptor.
Individual FcγR and allelic variants have restricted IgG 
isotype speciﬁ  city and different afﬁ  nities for the IgG iso-
types (Nimmerjahn and Ravetch 2005; Nimmerjahn et al 
2005). IgG1 binds the inhibitory FcγRIIB and the activat-
ing FcγRIII with low afﬁ  nity, thus favoring inhibition under Biologics: Targets & Therapy 2008:2(3) 538
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basal conditions, whereas IgG2a binds three activating FcγR, 
FcγRI, FcγRIV, and FcγRIII, with varying afﬁ  nities and binds 
inhibitory FcγRIIB with low afﬁ  nity, thus promoting cell 
activation. Notably, FcγR expression and IgG isotype are 
regulated by cytokines, and thus both can vary considerably 
during the course of disease and during therapy. Trans-
forming growth factor-beta, IL-4 and IL-10 downregulate 
activating FcγR and upregulate inhibitory FcγRIIB on most 
effector cells, and induce IgG1 and IgG3 isotypes. In con-
trast, interferon shifts the balance toward activating FcγR 
and production of IgG2a and IgG2b isotypes. Thus multiple 
factors determine the outcome of interactions between FcγR 
and IgG/immune complexes.
FcγR in GN and potential for therapeutic 
manipulation
In human GN there is evidence that FcγR susceptibility alleles 
predispose to disease. Perhaps most compelling, Aitman 
and colleagues demonstrated not only that copy number of 
the FcγRIIIB gene (FCGR3B) varies between individu-
als, ranging from none to four copies per cell, but that low 
FCGR3B copy number and particularly absence of FCGR3B 
is associated with susceptibility to lupus nephritis (Aitman 
et al 2006; Fanciulli et al 2007). Increased risk for lupus 
nephritis is also described with polymorphisms in FcγRIIB, 
FcγRIIA and FcγRIIIA in a subset of ethnic groups in some 
studies (Schwarting 2006).
Multiple observations in rodent experimental nephritis 
conﬁ  rm that engagement of activating FcγR promotes nephri-
tis whereas signaling via inhibitory FcγRIIB ameliorates 
disease. In the nephrotoxic serum nephritis (NSN) model, 
susceptible animals are administered heterologous antiserum 
reactive with recipient GBM. Disease onset is accelerated 
by prior immunization with species-speciﬁ  c IgG. Because 
antigen (foreign Ig) is planted in the glomerulus in NSN, this 
model is used primarily to study downstream effector mecha-
nisms that are recruited either by the deposited heterologous 
IgG or by the autologous anti-foreign-Ig immune response. 
In the Wistar Kyoto and related rat strains, susceptibility 
to NSN and macrophage hyperactivity is associated with a 
polymorphism in the activating FcγR, FcγRIIIB (Aitman et al 
2006). In murine NSN, disruption of the gene encoding the 
common FcγR gamma chain (FcγR-KO) renders activating 
FcγR nonfunctional and markedly improves survival and pre-
vents severe nephritis. Glomerular IgG and C3 deposits are 
unchanged in these mice, suggesting that protection involves 
interruption of events downstream of immune deposition 
(Park et al 1998; Wakayama et al 2000). Reciprocal bone 
marrow transplantation studies in murine accelerated NSN 
further show that protection depends on loss of FcγR expres-
sion on bone marrow-derived cells, presumably leukocytes 
(Tarzi et al 2002). Genetic deﬁ  ciency of activating FcγR 
also confers resistance to lupus nephritis in BWF1 mice, 
despite persistent serum autoantibodies and renal IgG and 
C3 deposits (Clynes et al 1998).
Mice administered monoclonal antibody to block activat-
ing receptor FcγRIV were also protected from NSN (Kaneko 
et al 2006a). FcγRIV-expressing macrophages are recruited 
to glomerular lesions in this model, suggesting that disease is 
modulated at the site of tissue injury. Protection was not seen 
with control antibody infusion, by genetic deletion of FcγRIII, 
or by combined deletion of the FcγRIII and FcγRI activating 
receptors. At the time of these studies a deletion model of 
FcγRIV was not yet developed. Administration of high dose 
intravenous immunoglobulin, or IVIG, the pooled puriﬁ  ed 
IgG fraction, or its Fc portion, also ameliorated nephritis 
in this model, concurrent with downregulated expression 
of FcγRIV on kidney-inﬁ  ltrating leukocytes (Kaneko et al 
2006a). IVIG also upregulated inhibitory FcγRIIB; how-
ever, anti-FcγRIV antibody therapy was effective in NSN in 
FcγRIIB-deﬁ  cient mice, conﬁ  rming a key role for FcγRIV in 
pathogenesis (Kaneko et al 2006a).
It is notable that the dominant activating FcγR engaged in 
NSN is model speciﬁ  c. C57BL/6 mice immunized with sheep 
IgG develop a dominant IgG2b mouse anti-sheep response 
(Kaneko et al 2006a). Mouse IgG2b binds both FcγRIV and 
FcγRIII, but with different afﬁ  nities. Induction of NSN in 
mutant C57BL/6 mice rendered genetically deﬁ  cient in these 
activating receptors revealed that FcγRIV is the major if not 
sole activating FcγR involved in pathogenesis in this model 
(Kaneko et al 2006a). In contrast, NSN induced in C57BL/6 
mice using rabbit nephrotoxic serum is FcγRIII dependent 
(Fujii et al 2003). Thus, features of the inciting antigen help 
determine the nature of the subsequent immune response.
In contrast to the proinﬂ  ammatory role of activating FcγR, 
the inhibitory receptor FcγRIIB is protective in several mod-
els of experimental nephritis. Genetic deletion of FcγRIIB 
accelerates mortality in murine NSN (Kaneko et al 2006a), 
and leads to severe crescentic GN and massive pulmonary 
hemorrhage in mice immunized with collagen, an induced 
model of human spontaneous autoimmune GPS (Nakamura 
et al 2000). Deletion of FcγRIIB also leads to spontaneous 
autoimmunity and nephritis in a strain-dependent manner 
in susceptible normal backgrounds (Bolland and Ravetch 
2000). FcγRIIB-deﬁ  cient C57BL/6 mice develop proteinuria, 
immune complex deposition nephritis, activated lymphocytes, Biologics: Targets & Therapy 2008:2(3) 539
Therapy for glomerulonephritis
anti-chromatin autoantibodies, multiorgan inﬂ  ammation, and 
early death. Conversely, deletion of FcγRIIB has no discern-
able phenotypic effect in the 129/B6 hybrid or BALB/c inbred 
backgrounds (Bolland and Ravetch 2000).
Protection afforded by FcγRIIB appears to include 
effects at the level of both effector cells and B cell tolerance. 
Amelioration of NSN by high dose IVIG is accompanied by 
upregulated expression of FcγRIIB on kidney-inﬁ  ltrating 
leukocytes (Kaneko et al 2006a), suggesting a direct effect 
on glomerular inﬂ  ammation. In contrast, development of 
autoantibodies and proteinuria in FcγRIIB-deﬁ  cient C57BL/6 
mice requires loss of FcγRIIB on B cells, not myeloid cells, 
as revealed by reciprocal bone marrow transfer experiments 
(Bolland and Ravetch 2000). This dual action is consistent 
with the roles of FcγRIIB in setting activation thresholds for 
both B cells and myeloid cells.
Conversely, enhancing expression of inhibitory FcγRIIB 
can restore tolerance and improve lupus nephritis. This 
approach was effective in three lupus strains, BXSB, NZM 
and B6.FcγRIIB-KO, subjected to isologous bone marrow 
transplantation (McGaha et al 2005). Donor bone marrow 
cells were transduced with vector carrying a DNA construct 
encoding FcγRIIB. B cell surface expression of FcγRIIB 
almost doubled in transplanted recipients. This was associ-
ated with signiﬁ  cantly improved survival, reduced protein-
uria, reduced autoantibody levels, reduced B cell activation, 
and improved nephritis and lung disease in each mouse 
strain compared to irradiated transplanted control mice that 
received mock-transduced bone marrow.
FcγRIIB may play a key pathogenic role in systemic lupus 
erythematosus, and lupus nephritis in particular. Reduced 
FcγRIIB expression on activated and germinal center B cells 
is reported in multiple strains of autoimmune mice, includ-
ing NZB, NOD, BXSB, and MRL. Low FcγRIIB expression 
has been linked to polymorphisms in the gene promoter 
(Nimmerjahn and Ravetch 2006). In human lupus, reduced 
FcγRIIB expression on activated B cells and inadequate 
upregulation of FcγRIIB on memory B cells are reported 
(Mackay et al 2006). These defects in man have been linked 
to polymorphisms in the FcγRIIB transmembrane domain 
that impair the ability of FcγRIIB to enter lipid rafts (Floto 
et al 2005; Kono et al 2005,).
Modulation of IgG glycosylation
in glomerular inﬂ  ammatory injury
IgG binding to FcγR requires Ig glycosylation (Kaneko 
et al 2006b). Over 30 different carbohydrate moieties cova-
lently attach to the IgG Fc region via an N-linked glycan at 
asparagine 297. These glycans can have potent effects on 
IgG effector functions. The addition of the terminal sialic 
acid residue decreases IgG binding to selected FcγR by 5- to 
10-fold. In an experimental model in which an anti-platelet 
IgG1 mediates cytotoxicity in vivo, enrichment for IgG sialic 
acid markedly reduces antibody efﬁ  cacy and minimizes 
platelet depletion (Kaneko et al 2006b).
IgG glycosylation is also important for the therapeutic 
efﬁ  cacy of IVIG. In an experimental arthritis model, enrich-
ment for sialic acid enhances IVIG efﬁ  cacy, such that a 
10-fold lower IVIG dose yields the same marked clinical 
improvement as does full dose nonenriched IVIG (Kaneko 
et al 2006b). In this arthritis model, the mechanism appears to 
involve sialic acid-enriched IVIG upregulation of inhibitory 
FcγRIIB on macrophages. Conversely, enzymatic removal 
of all carbohydrate residues from IVIG eliminates most of 
its efﬁ  cacy (Kaneko et al 2006b). These observations may 
explain the requirement for high doses of IVIG to achieve 
anti-inﬂ  ammatory effects clinically; terminally sialylated 
IgG normally comprises only 5% of total serum IgG, and 
thus of IVIG.
FcγR and IgG-based therapeutic 
strategies in GN
FcγR offer attractive targets for therapeutic modulation 
in nephritis. Potential approaches include blockade of the 
various activating FcγR using neutralizing monoclonal 
antibodies or small molecules, and upregulation or activa-
tion of inhibitory receptors, either on effector cells in target 
tissues or on pathogenic autoreactive B cells. IVIG is cur-
rently used therapeutically in nephritis primarily as salvage 
therapy in refractory disease (Toubi et al 2005). Recent 
advances in our understanding of mechanisms of action 
of IVIG provide a blueprint for enhancing its efﬁ  cacy by 
glyco-engineering antibody preparations and selectively 
enriching for desired isotypes. Gene therapy combined with 
isologous bone marrow transplantation, an approach used to 
enhance FcγRIIB expression in rodents, is feasible in man. 
Ultimately, a tailored approach in which FcγR-directed 
therapy takes into account the IgG isotype that dominates 
a given disease, the type of effector cells engaged, and the 
disease- or patient-speciﬁ  c FcγR proﬁ  le has the potential to 
revolutionize therapy in GN.
Complement and GN
Glomerular complement deposition is common in immune 
complex mediated glomerular injury. Targeting complement 
for intervention, however, requires understanding of the Biologics: Targets & Therapy 2008:2(3) 540
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complexity and diverse functions of the complement system 
(Gasque 2004). Over 30 proteins are engaged in the three 
major pathways of complement activation that converge on 
components C3, C5 and the terminal pathway that gener-
ates the C5b-9 membrane attack complex, or MAC: (1) The 
classical pathway initiated by immune complex recruitment 
of C1q, C4 and C2; (2) The alternative pathway in which 
activating surfaces engage C3b and factors B and D; and, 
(3) The lectin pathway in which activation depends on 
microbial carbohydrate interaction with mannose-binding 
ligand. Activation generates: the anaphylatoxins C3a and C5a 
that engage speciﬁ  c cell membrane receptors, C3aR and 
C5aR; C3b that associates with immune complexes; and, the 
C5b-9 membrane attack complex, or MAC, that inserts into 
cell membranes to induce sublytic or lytic injury. Comple-
ment activation is in turn regulated by a cadre of widely 
distributed soluble (factor H, C4bp) and cell-bound (decay 
accelerating factor or DAF, membrane cofactor protein or 
MCP, CR1, CD59, and rodent CR1-related gene/protein y 
or Crry) complement inhibitors. Local renal production of 
complement components, constitutive and inducible renal cell 
expression of complement receptors and regulatory proteins, 
and accessibility of locally activated complement proteins to 
circulating or inﬁ  ltrating receptor-bearing leukocytes inﬂ  u-
ences the nephritis phenotype.
Complement proteins mediate a variety of key functions 
that promote immunity and inﬂ  ammation to protect the host 
from microorganisms. These same functions occasionally 
induce autoimmunity and organ damage. Complement acti-
vation leads to adjacent cell activation, sublytic injury or 
death, myeloid cell chemotaxis and activation, and enhanced 
T-dependent humoral responses. The complement system can 
also dampen inﬂ  ammation and immunity, by solubilizing, 
clearing and processing antigen, immune complexes and 
apoptotic debris, by regulating B cell responses, and by help-
ing to maintain B cell tolerance. Because of these divergent 
functions, the therapeutic potential of complement inhibitors 
in nephritis is complex.
This intricacy is reﬂ  ected in the paradoxical roles of com-
plement in lupus nephritis. A pathogenic role is supported by 
the presence of C1q and C3 in inﬂ  amed glomeruli and cor-
relation of low serum C3 and C4 levels with disease activity. 
Yet deﬁ  ciency, not excess, of complement components C1q, 
C2 or C4 predisposes to SLE. This paradox is due in part to 
the primarily protective role of the early classical complement 
pathway. Genetic deﬁ  ciency of C1q or C4 worsens nephritis 
and autoimmunity in murine lupus, and leads to spontane-
ous onset of autoimmune GN in susceptible normal strains 
(Botto et al 1998; Prodeus et al 1998; Chen et al 2000; Einav 
et al 2002; Mitchell et al 2002; Paul et al 2002).
Conversely, the alternative pathway may contribute to 
renal damage. Genetic deﬁ  ciency of factor B or factor D 
improves lupus nephritis in the MRL/lpr strain (Watanabe 
et al 2000; Elliott et al 2004), suggesting a predominantly 
pathogenic role for these components. The alternative 
pathway is also implicated in a subset of patients with mem-
branoproliferative GN, or MPGN, types I and II. Genetic 
deﬁ  ciency of the soluble complement regulatory protein, 
Factor H, leads to continuous complement activation and C3 
turnover in vivo. Pigs and mice with this deﬁ  ciency develop 
MPGN that is amenable to therapy with anti-C5 monoclonal 
antibody (Hogasen et al 1995; Jansen et al 1998; Pickering 
et al 2002, 2006). A similar pathogenesis is suspected in the 
subset of patients with MPGN who have deﬁ  cient factor H 
activity due either to mutations in Factor H, to anti-factor 
H autoantibodies, or to C3 nephritic factor (C3NeF), an 
autoantibody that binds and stabilizes the alternative path-
way C3bBb convertase (Meri et al 1992; Dragon-Durey et al 
2004; Zipfel et al 2006).
Results in murine MRL/lpr lupus using blockade of C3, 
a common central component of the complement pathways, 
are inconsistent. Genetic deﬁ  ciency of C3 worsens nephri-
tis, suggesting a primarily protective role, similar to that 
proposed for C1q and C4 (Sekine et al 2001). In contrast, 
administration of the rodent C3 inhibitor Crry (CR1-related 
gene/protein y), either as a Crry-Ig fusion protein or in the 
form of transgenic soluble Crry, improves nephritis, consis-
tent with a pathogenic role for C3 (Bao et al 2002, 2003).
The contribution of complement to pathogenicity in 
murine anti-GBM disease is equally complex. Deﬁ  ciency 
of either C3 or C4 protects against nephritis in the heter-
ologous phase of NSN (Sheerin et al 1997). Conversely, in 
the autologous phase of disease or in accelerated NSN, C3 
deﬁ  cient mice develop worse nephritis (Sheerin et al 2001). 
Deﬁ  ciency of complement regulators CD59, a terminal path-
way inhibitor, CD55 (decay accelerating factor, or DAF), 
a C3 inhibitor, double deﬁ  ciency of CD59 and CD55, or 
double deﬁ  ciency of CD55 and Crry exacerbates nephritis 
or proteinuria in murine NSN (Turnberg et al 2003; Lin et al 
2004; Miwa et al 2007).
These diverse outcomes reﬂ  ect the diverse roles for 
complement at multiple checkpoints during the immune 
response, including modulation of B cell activation, inﬂ  am-
mation, and immune complex clearance. Additionally, 
some of these discrepancies may be the result of gaps in 
our understanding of complement biology. In this regard, Biologics: Targets & Therapy 2008:2(3) 541
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Huber-Lang et al recently proposed a fourth pathway for 
complement activation that bypasses C3 (Huber-Lang et al 
2006). This novel pathway depends on thrombin and tissue 
factor to independently generate C5 convertase to activate 
C5 and the terminal pathway. Lung injury induced by air-
way instillation of IgG immune complexes was equivalent 
in C3-sufﬁ  cient and C3-deﬁ  cient mice. Importantly, severe 
lung disease was ameliorated in both cases by administering 
antibody speciﬁ  c for C5a.
Renal injury resulting from the membrane attack com-
plex, MAC or C5b-9, is best characterized in the noninﬂ  am-
matory passive Heymann nephritis model of membranous 
nephropathy induced in susceptible rat strains by injection of 
heterologous antiserum. Proteinuria is largely dependent on 
in situ complement activation triggered by podocyte-bound 
IgG, leading to insertion of the MAC into the podocyte 
membrane and subsequent cell activation, sublytic injury 
and release of soluble mediators (Cybulsky et al 1986, 2005). 
By analogy, it is proposed that proteinuria in patients with 
MN is predominantly MAC-dependent, a view supported by 
demonstration of MAC in patient urine and renal biopsies 
(Schulze et al 1991). Interindividual and strain-dependent 
differences in mechanisms of proteinuria are likely, however, 
because proteinuria develops in active Heymann nephritis 
induced in the complement C6-deﬁ  cient PVG/c rat strain 
(Leenaerts et al 1995).
Complement therapeutics in GN
Although as yet no complement-directed therapy has proven 
efﬁ  cacy in nephritis, a variety of complement inhibitors are 
under development or in clinical trials in human autoimmune 
and inﬂ  ammatory diseases (Morgan and Harris 2003; Turn-
berg and Cook 2005; Ricklin and Lambris, 2007). Inhibitors 
being tested include recombinant soluble forms of naturally 
occurring inhibitors, soluble complement receptor 1 (CR1), 
small molecule inhibitors of C3, blocking antibodies or single 
chain Ig Fv fragments against complement components such 
as C5, inhibitors of serine proteases, and anaphylatoxin 
analogues to antagonize C3aR or C5aR. Realization that 
early components of the classical complement pathway have 
major protective roles in preventing autoimmunity has shifted 
focus in nephritis to inhibition of the alternative pathway or 
downstream complement components and local enhancement 
of complement inhibitors.
Anti-C5 antibody blocks generation of C5a fragment, 
C5b and the MAC. Anti-C5 Ig ameliorates lupus nephritis 
in the BWF1 strain and nephrotoxic serum nephritis in factor 
H-deﬁ  cient mice (Wang et al 1996, Pickering et al 2006). 
Prevention of spontaneous MPGN type II by disruption of 
the C5 gene in factor H-deﬁ  cient mice suggests that anti-C5 
antibody therapy may also be effective in the subset of MPGN 
patients with aberrant factor H activity (Pickering et al 2006; 
Smith et al 2007). The humanized monoclonal antibody to 
C5, eculizumab (Alexion), was approved by the FDA in early 
2007 for use in patients with chronic hemolytic anemia due 
to paroxysmal nocturnal hemoglobinuria, an acquired genetic 
deﬁ  ciency of complement inhibitors (Ricklin and Lambris, 
2007). Eculizumab was well tolerated in patients with MN 
but a relatively short four month course failed to signiﬁ  cantly 
reduce proteinuria (Appel et al 2002). The efﬁ  cacy of anti-
C5 antibody therapy in other human glomerular diseases is 
yet to be established.
Systemically administered inhibitors that bind the C5aR 
are in preclinical studies. C5aR is expressed on monocytes, 
neutrophils and cultured human mesangial cells (Braun and 
Davis, 1998) and increased in lupus nephritis kidneys (Abe 
et al 2001; Bao et al 2005). Pharmacological C5aR blockade 
using a small molecule antagonist prevents progressive lupus 
nephritis in MRL/lpr mice (Bao et al 2005).
Alternative strategies that target the site of complement 
activation and tissue injury in vivo are in development. 
Targeting permits local concentration of inhibitor while 
avoiding systemic effects that may compromise host defense 
or important physiological functions of C3 or C5. Efﬁ  cacy 
was demonstrated in experimental proteinuria-induced renal 
tubulointerstitial injury using rat Crry or CD59 linked to a 
single chain Fv that targeted a rat proximal tubular epithelial 
cell antigen (He et al 2005). A fusion protein engineered to 
link complement receptor 2 (CR2), a binding partner for C3 
activation fragments, to a soluble form of the membrane 
complement inhibitor DAF successfully targeted the inhibitor 
to inﬂ  amed kidney in mouse models of lupus nephritis (Song 
et al 2003). Ongoing investigation is dissecting the contribu-
tions of locally expressed complement components, receptors 
and regulatory proteins in experimental and human nephritis. 
It is anticipated that knowledge of the biology of complement 
in individual nephritides, throughout the course of disease 
and during concurrent immunosuppressive therapy, will 
ultimately permit appropriate therapeutic targeting.
Summary and conclusion
GN is a common cause of renal injury and CKD that con-
tinues to rely on non speciﬁ  c immunosuppression for thera-
peutic intervention. Recent insights into underlying biology 
and disease pathogenesis in human nephritis combined with 
advances in the ﬁ  elds of inﬂ  ammation and autoimmunity Biologics: Targets & Therapy 2008:2(3) 542
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bring the promise of new therapies. Notable breakthroughs 
include the discovery that alloimmunity to a glomerular 
antigen underlies antenatal membranous nephropathy, that 
podocytes are key regulators of glomerular ﬁ  ltration, that 
complement inhibitors are pivotal to pathogenesis in MPGN, 
and that IgG Fc receptors form a crucial link between anti-
body deposition and tissue injury. These discoveries provide 
the basis for novel therapies based on speciﬁ  c antigen or 
antibody responses or dominant effector cells or molecules 
engaged in individual nephritides. Future additional insights 
into cellular immunity, immune tolerance and regulatory net-
works, effector mechanisms, and genetic and environmental 
disease susceptibility will extend this armamentarium and 
provide the foundation for tailored individualized therapy.
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